-
VHL Europa Welcomes CHMP’s Positive Opinion for Belzutifan as First Systemic Treatment for VHL Patients
16 December 2024
VHL Europa, representing the voice of von Hippel-Lindau (VHL) patients across Europe, is thrilled by the news that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval of WELIREG® (belzutifan). If approved, belzutifan will become the first systemic treatment available for adult patients…
-
Long-Term Treatment for VHL-Associated Brain and Spine Tumours?
25 November 2024
This study investigated the effectiveness of belzutifan, a daily oral medication, in treating central nervous system (CNS) haemangioblastomas associated with VHL disease, usually in the brain and along the spine. Researchers followed patients for over three years to assess how well the treatment reduced tumour size and its safety profile. Among the 50 patients with…
-
Meeting Report: VHL International Medical Research Conference, 19-20 October 2024, Milan, Italy
19 October 2024
Our journey to Milan for the VHL International Medical Research Conference began on a rainy Friday, 18 October. A public transport strike made for a complicated arrival, we finally got to the hotel across town. We held our Annual General Assembly for VHL in the hotel in the evening of October 18th, 2024, with members…
-
VHL Europe launches new patient support program
3 October 2024
In an effort to provide even more comprehensize support, VHL Europe has introduced a new program to offer patient support. Cras finibus faucibus dui, ac pharetra lectus volutpat non. Vestibulum vitae imperdiet turpis. Donec in nulla vel turpis tincidunt volutpat eget et lacus. Integer nunc mauris, sollicitudin quis facilisis a, accumsan rutrum massa. Curabitur in…
